Estrogen News and Research

Latest Estrogen News and Research

Confusing risk information may lead breast cancer patients to make poor treatment choices

A new study from researchers at the University of Michigan Comprehensive Cancer Center found that a tool commonly used by doctors to estimate the risk of a woman's breast cancer returning after surgery is not very effective at explaining risk to patients.

8 Dec 2008

Azur Pharma to acquire U.S. rights to Elestrin

Azur Pharma Limited has announced that it has entered into a definitive agreement with BioSante Pharmaceuticals, Inc to acquire U.S. rights to Elestrin.

8 Dec 2008

Migraines linked to lower risk of breast cancer

Women who suffer from migraines may take at least some comfort in a recent, first-of-its-kind study that suggests a history of such headaches is associated with a significantly lower risk of breast cancer. Christopher I. Li, M.D., Ph.D., and colleagues at Fred Hutchinson Cancer Research Center report these findings in the November issue of Cancer Epidemiology, Biomarkers and Prevention.

7 Dec 2008

Stereotypical imperfections offer health benefits when it comes to bodies

Having an imperfect body may come with some substantial benefits for some women, according to a new article in the December issue of Current Anthropology.

3 Dec 2008

Anti-oestrogen drugs may promote more harmful cancer cell behaviour

The authors found that tamoxifen can promote an invasive phenotype in ER+ breast cancer cells under conditions of poor cell-cell contact, a previously unknown effect of this drug

3 Dec 2008

New cream for vaginal dryness approved

Barr Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its subsidiary Duramed Pharmaceuticals, Inc.'s New Drug Application (NDA) for Synthetic Conjugated Estrogens-A (SCE-A) 0.625 mg/g Vaginal Cream.

1 Dec 2008

Hormone therapy could be dangerous for women pre-existing heart disease risk factors

Hormone therapy could accentuate certain pre-existing heart disease risk factors and a heart health evaluation should become the norm when considering estrogen replacement, new research suggests.

25 Nov 2008

How to handle the menopause - eat less, get more active and wear HRT skin patches

The latest advice to women going through the menopause is eat less, get more active and consider wearing hormone replacement therapy (HRT) skin patches.

25 Nov 2008

Weight gain during menopause

Weight and appetite experts from around the world met at a conference in Bangkok earlier this year to discuss sex differences in obesity.

24 Nov 2008

Study identifies causes of bone loss in breast cancer survivors

Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss.

19 Nov 2008

Breakthrough reveals first ever complete structure of a nuclear hormone receptor on human DNA

For decades, scientists have been studying nuclear hormone receptors to gain a better understanding of how they turn genes on and off throughout the body and how they function as key drug targets for a number of diseases, such as diabetes, breast cancer, osteoporosis and high cholesterol. A new UVA Health System study, led by Fraydoon Rastinejad, Ph.D., professor of pharmacology and director of the UVA Center for Molecular Design and published in the October 29 issue of Nature, reveals the first ever complete structure of a nuclear hormone receptor on human DNA – a discovery that now clears a new path for scientists to design more effective drugs with fewer associated health risks. “Dr. Rastinejad’s findings fundamentally change the way people all over the world will study how nuclear hormone receptors work and introduces a new platform for designing better drugs,” says Jim Garrison, Ph.D., professor of pharmacology at UVA Health System. Nuclear hormone receptors, including the peroxisome proliferator-activated receptors (PPARs), are proteins that sit on the surface of cells and bind to specific hormones such as estrogen, progesterone and thyroid hormone. Once the receptor binds to its hormone and its DNA regulatory element, it can cause a number of alterations in the cell, switching genes on and off. These switches control the continual regulation of the metabolic system and reproductive tissues, as well as the development and differentiation of skin, bone and behavioral centers in the brain. “PPARs are widely studied because they regulate the genes that produce fat cells, glucose, insulin, lipids and metabolism,” says Dr. Rastinejad. “That’s what makes them such good drug targets for diseases like diabetes. We can design drugs more rationally to bind to the PPAR nuclear receptor complex to help regulate these functions in the body.” A number of diabetes drugs, called insulin sensitizers, have been developed based on that knowledge, but now that scientists have a clear view into how these receptors bind and what shape they take the door is wide open for the development of better drugs. "After 40 years of nuclear receptor research, we finally can view the first full and complete structure of a nuclear receptor, thanks to Dr. Rastinejad’s break-though achievement,” says Bert W. O’Malley, Ph.D., professor and chairman, Department of Molecular and Cellular Biology at Baylor College of Medicine who is widely considered a top expert in the field.

17 Nov 2008

Scientists find intra cellular pathway driving a deadly sub-type of breast cancer

An intra cellular pathway not previously linked to breast cancer is driving a sub-type of the disease that is highly lethal and disproportionately over-represented in African American women.

16 Nov 2008

Researchers evaluate root canals versus extraction and dental implants

A new study addresses the growing controversy among dental health professionals regarding the best course of treatment when evaluating between a root canal or dental implant procedure.

16 Nov 2008

Osteoporosis drugs may prevent future bone growth

Patients who start and eventually stop regimens of a common class of osteoporosis drugs called bisphosphonates may be unable to benefit from parathyroid hormone (PTH), which can rebuild bone mass lost due to advanced stage osteoporosis. PTH has been proven to increase the volume and strength of the honeycomb-like bone infrastructure, the inner mesh that begins to diminish in old age.

13 Nov 2008

Scientists crack the code to tamoxifen resistance

CANCER RESEARCH UK scientists have discovered the molecular basis for tamoxifen response in breast cancer cells - and the reason why some women can develop resistance to the treatment, according to a study published in Nature today (Wednesday).

12 Nov 2008

Sex hormones may affect atherosclerosis

Naturally produced sex hormones may influence the risk and progression of atherosclerosis, or hardening of the arteries, Johns Hopkins researchers report in a recent study.

11 Nov 2008

Flu shots cut the risk of blood clots forming in veins

According to new research by French scientists flu shots may reduce the risk of venous thrombotic embolism.

10 Nov 2008

Testosterone patches charge up older women's sex

According to research by an international team of scientists testosterone could recharge the sex lives of older women.

10 Nov 2008

Flu shots may reduce risk of blood clots forming in veins

Flu shots may reduce the risk of blood clots forming in veins by 26 percent, according to research presented at the American Heart Association's Scientific Sessions 2008.

10 Nov 2008

Chronic kidney disease and women's sexuality and gynecologic health

Chronic kidney disease (CKD) exacts a significant toll on a woman's sexuality and gynecologic health. The various effects of kidney failure and its treatments on women's sexual health from adolescence through menopause will be the topic of an in-depth series of presentations at the American Society of Nephrology's 41st Annual Meeting and Scientific Exposition in Philadelphia, Pennsylvania.

8 Nov 2008